Morphosys and Oncomed sign HuCal Gold licensing deal
Germany's MorphoSys AG and US biopharmaceutical company OncoMed say they have signed a licensing deal under which the former's HuCal Gold antibody library is licensed to the latter for use in the development of a variety of cancer therapeutics.
The HuCal technology uses in vitro generation to synthesize fully-human antibodies for screening against a wide range of therapeutic targets. Under the terms of the deal, OncoMed is entitled to carry out commercial development of antibodies that it identifies, in return for the payment of an upfront license fee, developmental milestone payments and royalties based on resulting sales. Financial terms of the accord were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze